Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
View original at globenewswire.comTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TPST-2003 represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy
60% confidenceThe parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative
60% confidenceTempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year
60% confidenceA total of 36 patients with rrMM had received one infusion of TPST-2003 as of January 31, 2026, including 24 patients in IIT and 12 patients in REDEEM-1
60% confidenceAll activities other than long-term stability testing planned to be complete in Q3 2026
60% confidenceThe potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T is particularly exciting
60% confidenceThe recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for rrMM
60% confidenceThe parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative
60% confidenceTPST-2003 has the potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T
60% confidenceAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026
60% confidenceThis represents one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy
60% confidenceThe recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for relapsed/refractory multiple myeloma
60% confidenceTempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year
60% confidenceTotal of 36 patients with relapsed/refractory multiple myeloma had received one infusion of TPST-2003 as of January 31, 2026 data cutoff, including 24 patients in prior Phase 1/2 investigator-initiated trial and 12 patients in ongoing REDEEM-1 trial
60% confidence